Ken Herrmann, Chair of the Department of Nuclear Medicine at University Hospital Essen, shared on LinkedIn:
“FDA Approval has different ways of success. Here we discuss at least some of them. Please join my guests Thomas Hope and Aman Chauhan and me to discuss “the equivalents”. I personally learnt a lot!
Thanks to Curium Pharma for the support”
To which Aman Chauhan, Associate Professor at the University of California, San Francisco, added:
“It was great to interact with my Nuclear Medicine colleagues on this important topic.
We may not all agree on the choice of terminology or even whether distinct terms are needed to describe drugs emerging through different regulatory approval pathways, but it was a valuable discussion and a great exercise in highlighting the nuances of these various pathways.”
Title: The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond
Authors: Aman Chauhan, Andrew E Hendifar, Ghassan El-Haddad, Heloisa P Soares, Ken Herrmann
You can also read ‘Aktis Advances Radiopharmaceutical Pipeline With AKY-2519 FDA Clearance‘
